Ciprofloxacin / dexamethasone

The selected suspension treats acute otitis media in children age 6 months and older WITH tympanostomy tubes due to susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, or Pseudomonas aeruginosa. It also treats acute otitis externa from age 6 months through adults/older adults due to susceptible S. aureus or P. aeruginosa. The AOM indication is pediatric and tube-specific; do not extend it automatically to AOM behind an intact tympanic membrane.

This profile covers ciprofloxacin 0.3% / dexamethasone 0.1% sterile otic suspension, commonly associated with the brand Ciprodex. It does not cover oral/IV ciprofloxacin, ophthalmic ciprofloxacin, ciprofloxacin/hydrocortisone, or other combinations. Treat an appropriate bacterial diagnosis and reassess failure; it is not therapy for viral or fungal canal infection.

Instill FOUR drops into the affected ear twice daily for 7 days for either labeled condition. Four drops equal approximately 0.14 mL, containing 0.42 mg ciprofloxacin and 0.14 mg dexamethasone. Repeat in the other ear only if it is also being treated. Use the prescribed full course, and discard the unused portion afterward.

Hold the bottle in the hand for 1–2 minutes to reduce cold-drop dizziness, then shake well immediately before use. Lie with the affected ear upward and instill drops without touching the tip. For AOM with tubes, pump the tragus inward FIVE times to facilitate middle-ear penetration. Maintain the ear-up position for 60 seconds for either condition. For AOE the selected instructions describe gently pulling the outer ear lobe upward and backward. Do not add the tube-specific tragus maneuver as a required AOE step.

Use only in the ear; never in the eye or by injection. Children below 6 months have no established label efficacy/safety. The label does not provide a renal/hepatic adjustment, longer empiric course, or universal adult tube-AOM regimen; reassess rather than importing systemic ciprofloxacin doses.

Contraindicated with hypersensitivity to ciprofloxacin, other quinolones, or any component. Viral infections of the external canal, including herpes simplex, and fungal otic infections are also contraindications.

The selected otic combination label has no boxed warning. Do not transfer the systemic fluoroquinolone boxed warning wholesale to this local product; its own hypersensitivity, overgrowth, and route restrictions still apply.

AOM-tube trials commonly reported ear discomfort or pain; AOE trials reported itching, debris, superimposed infection, congestion, pain, or redness. Postmarketing reports include auricular swelling, headache, hypersensitivity, drainage, peeling, rash, or vomiting, without reliable frequency estimates. The label expects no toxic effects from an otic overdose based on preparation characteristics; this is not an ingestion, eye-use, or injection safety statement. Assess accidental wrong-route exposure separately.

No dedicated drug-interaction section or numeric interaction-adjustment algorithm is supplied in this selected label. Systemic absorption is measurable but far below oral ciprofloxacin exposure in the small pediatric study. Do not automatically assign oral ciprofloxacin chelation restrictions, CYP effects, renal schedules, or steroid-interaction doses to an ear-drop course. This is a limit of product evidence, not proof that every combination has been studied.

Confirm the exact active ingredients and route when reconciling other ear products; this sterile antibiotic/steroid suspension is not ciprofloxacin/hydrocortisone or an ophthalmic solution. For prolonged use or poor response, assess culture results and microbial overgrowth rather than simply layering more antimicrobial drops or extending treatment.

There are no adequate human pregnancy-use data; the label expects minimal maternal/fetal toxicity because otic absorption is low. Human milk transfer after otic use is unknown. Breastfeeding is not expected to expose the infant to ciprofloxacin, but dexamethasone milk exposure is uncertain and systemic steroids can affect growth/adrenal production. Consider maternal need, breastfeeding benefits, and infant risk rather than declaring zero exposure.

Safety and efficacy are established from age 6 months for the specified labeled conditions. A small audiometry assessment in children age 4–12 found no clinically relevant hearing changes; this does not prove safety of every ear product or indefinite treatment. AOE indication includes older adults, while the selected label has no dedicated geriatric dose adjustment. Pediatric tube-AOM indication is not broadened by the adult AOE approval.

The selected local-product label supplies no impairment-specific study or numeric renal/hepatic dosing algorithm. Use the labeled otic regimen for its indication and assess individual circumstances; do not borrow oral/IV ciprofloxacin adjustments or claim an impairment study established “no adjustment.”

Ciprofloxacin inhibits bacterial DNA gyrase required for DNA synthesis. Dexamethasone suppresses inflammatory cytokines and associated edema/leakage. Cross-resistance can occur with other fluoroquinolones; susceptibility remains relevant. The steroid supports resolution of inflammation but does not create antiviral or antifungal coverage.

After a single bilateral 4-drop dose in nine children after tube insertion, mean peak ciprofloxacin was 1.39 ng/mL, roughly 0.1% of the peak after a 250 mg oral dose; mean dexamethasone peak was 1.14 ng/mL, approximately 14% of the cited oral 0.5 mg peak. Peaks occurred within 15 minutes to 2 hours. These small-study comparisons are not dose conversions. Controlled trials support 7-day twice-daily treatment for the specified AOM-tube and AOE populations.

Assess clinical response by 1 week, allergy, fungal/nonsusceptible overgrowth, and recurrent or persistent drainage. Obtain cultures for non-improvement and evaluate underlying pathology after persistent full-course drainage or repeated episodes. Review tube status, correct diagnosis, dosing, and technique. Routine systemic ciprofloxacin drug-level or organ-laboratory monitoring is not established by this otic label.

Use in ears only. Warm in the hand, shake, keep the tip from contacting fingers or ear material, and maintain position for the instructed interval. Do not stop early simply because symptoms improve; do not extend the course without reassessment. Stop for rash/allergy and contact the clinician promptly; severe airway or collapse symptoms require urgent help. Protect from light and discard leftover drops when the course ends.

The current selected official SPL is Sportpharm relabeling of Dr. Reddy’s product: white/off-white suspension, 7.5 mL fill in a 10 mL plastic squeeze bottle with dropper and tamper-evident cap. Relabeler NDC 85766-245-75 is from source NDC 43598-326-75; SPL metadata lists ANDA205548. This is an identified generic-label product, not a claim that its bottle is branded Ciprodex or that every manufacturer shares its NDC.

Sterile otic suspension contains ciprofloxacin hydrochloride equivalent to 3 mg ciprofloxacin base/mL (0.3%) plus dexamethasone 1 mg/mL (0.1%). Benzalkonium chloride 0.1 mg/mL is the preservative. It is not an oral medicine, injectable preparation, or ophthalmic product; vehicle and route remain part of product identity.

Store at 20–25°C with 15–30°C excursions permitted. Avoid freezing and protect from light. Shake immediately before each use, avoid tip contamination, and discard the unused portion after completing therapy.